About Megan Krench
Megan Krench is a director at Memento Medicines.
Form D filings also name Megan Krench as a director at Veralox Therapeutics.
Megan Krench first appears on SEC filings in 2023.
Experience
This experience comes from Megan Krench's profile and from SEC filings. For roles taken from filings, the years are when the filings name Megan Krench in the role, so the role may have started earlier or lasted longer.
Memento Medicines, Inc. Current
Director
2026 – Present · Boston, MA
Develops antibody therapies for people with retinal diseases.
KB
Korsana Biosciences Current
Board Observer
2025 – Present
DT
Draig Therapeutics Current
Board Observer
2025 – Present
EB
Eligo Bioscience Current
Director
2023 – Present
QU
QurAlis Current
Board Observer
2023 – Present
NO
Normunity Current
Director
2022 – Present
SA
Sanofi Current
Investor, Sanofi Ventures
2021 – Present
NN
New England Venture Network Current
Board Co-Chair, Board Director
2019 – Present
AT
Aliada Therapeutics
Board Observer
2022 – 2024
VP
Vertex Pharmaceuticals
Director of BD - External Innovation
2020 – 2021
RP
RA Capital Management, L.P.
Senior Associate
2016 – 2020
HD
HDBuzz
Writer
2015 – 2016
CA
CBT Advisors
Consulting Intern
2014 – 2016
TU
Tufts University
Visiting lecturer
2013 – 2016
MM
MIT Museum
Instructor
2009 – 2016
MT
Massachusetts Institute of Technology
Neuroscience PhD
2009 – 2016
SA
Scientific American
Writer
2013
Key Colleagues at Startups
The people Megan Krench works with at each company, as listed on that company's latest Form D.
Memento Medicines, Inc. · Form D, Jun 16, 2026
ZS
Zach Scheiner
Director
WB
William Bonificio
Executive officer and promoter
ST
Stephen Thomas
Executive officer and promoter
DH
Dmitrij Hristodorov
Director
ND
Naveen Daryani
CEO and director
VK
Vishal Kapoor
Director
Veralox Therapeutics Inc. · Form D, Jun 21, 2023
AM
Alex Martin
Director
BS
Benjamin Scruggs
Director
JS
Jamie Stiff
Director
KE
Katie Ellias
Director
JM
Jonathan Mow
Chief Executive Officer and director